Clinical Implementation of Pharmacogenomics Through a
... child. Each time a gene test result is placed into your/your child’s St. Jude Children’s Research Hospital medical record, you chose to receive a letter notifying you of the result. Because your genes stay the same even as you age, the results may affect how doctors prescribe medicines for you/yo ...
... child. Each time a gene test result is placed into your/your child’s St. Jude Children’s Research Hospital medical record, you chose to receive a letter notifying you of the result. Because your genes stay the same even as you age, the results may affect how doctors prescribe medicines for you/yo ...
Gingko biloba Extended Abstract
... cycle, onset of symptoms in a cycle and the number of roommates. None of the participants were employed. All participants were compliant with the medications. Overall severity of symptoms in the experiment group was 34.80 +/- 12.02% before the intervention was reduced to 11.11 +- 5.74% after the in ...
... cycle, onset of symptoms in a cycle and the number of roommates. None of the participants were employed. All participants were compliant with the medications. Overall severity of symptoms in the experiment group was 34.80 +/- 12.02% before the intervention was reduced to 11.11 +- 5.74% after the in ...
Annotating and Recognising Named Entities in Clinical Notes
... and map biomedical terms to ontologies. However, clinical terms such as findings, procedures and drugs have received less attention. Although different approaches have been proposed to identify clinical concepts and map them to terminologies (Aronson, 2001; Hazlehurst et al., 2005; Friedman et al., ...
... and map biomedical terms to ontologies. However, clinical terms such as findings, procedures and drugs have received less attention. Although different approaches have been proposed to identify clinical concepts and map them to terminologies (Aronson, 2001; Hazlehurst et al., 2005; Friedman et al., ...
Roflex™ InViva™ COPD Anxiety Disorders
... neuropsychiatric conditions for the general clinical population. Therefore, our product, InViva™10 , will become the first new generation anxiolytic medication in decades. There is a serious need for a safe and effective pharmaceutical treatment for chronic anxiety. According to the National Institu ...
... neuropsychiatric conditions for the general clinical population. Therefore, our product, InViva™10 , will become the first new generation anxiolytic medication in decades. There is a serious need for a safe and effective pharmaceutical treatment for chronic anxiety. According to the National Institu ...
Diarrhoea +/- vomiting
... Use of oral rehydration solution is the recommended first line therapy for treating mild to moderate dehydration in children with gastroenteritis.2,11 Enteral (oral or nasogastric) rehydration is a much safer means of rehydration compared with intravenous rehydration because it ...
... Use of oral rehydration solution is the recommended first line therapy for treating mild to moderate dehydration in children with gastroenteritis.2,11 Enteral (oral or nasogastric) rehydration is a much safer means of rehydration compared with intravenous rehydration because it ...
Herb-drug interactions
... herbs – Scutellaria species – induction of CYP2E1, 2C9. Angelica dahurica – inhibited CYP1A2 (but no effect of Angelica tenuissima). ► Hundreds of other Asian herbs with no info on drug interactions, as well as many herbs from other medical traditions. ...
... herbs – Scutellaria species – induction of CYP2E1, 2C9. Angelica dahurica – inhibited CYP1A2 (but no effect of Angelica tenuissima). ► Hundreds of other Asian herbs with no info on drug interactions, as well as many herbs from other medical traditions. ...
Curriculum Vitae - Chesapeake Research Group
... A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group, 6-Week Study to Evaluate the Effect of Multiple Doses of (the study drug) twice daily, Prednisone and Placebo on the HypothalamicPituitary-Adrenal Axis in Adult Subjects with Mild to Moderate Asthma ** Javelin Pharmaceutical ...
... A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group, 6-Week Study to Evaluate the Effect of Multiple Doses of (the study drug) twice daily, Prednisone and Placebo on the HypothalamicPituitary-Adrenal Axis in Adult Subjects with Mild to Moderate Asthma ** Javelin Pharmaceutical ...
GlycoGenesys, Inc. $1.10 BUY
... Figure 8: Overall GCS-100 Structure............................................................................................19 Figure 9: Anti-metastasis ..............................................................................................................20 Figure 10: Dose Dependent Tumor ...
... Figure 8: Overall GCS-100 Structure............................................................................................19 Figure 9: Anti-metastasis ..............................................................................................................20 Figure 10: Dose Dependent Tumor ...
SDSP-001 - PhUSE Wiki
... Standardization Plan (Standardization Plan) assists FDA in identifying potential data standardization issues early in the development program1. ...
... Standardization Plan (Standardization Plan) assists FDA in identifying potential data standardization issues early in the development program1. ...
The Urgent Need Regenerating antibacterial drug
... and brought to market between 1983-1987, compared with the estimate that between only two and four new antibacterial agents will reach market between 2008-2012. It is by no means clear if even these will address the current clinical issues. The Urgent Need initiative was established in response to t ...
... and brought to market between 1983-1987, compared with the estimate that between only two and four new antibacterial agents will reach market between 2008-2012. It is by no means clear if even these will address the current clinical issues. The Urgent Need initiative was established in response to t ...
Methods for therapeutic trials in COPD: lessons from the TORCH trial PERSPECTIVE
... analysis requires inclusion of all available subjects in the analysis. In principle there should also be complete follow-up of all patients [6] but, in practice, for outcomes other than mortality there are nearly always missing data. The CONSORT (Consolidating Standards of Reporting Trials) statemen ...
... analysis requires inclusion of all available subjects in the analysis. In principle there should also be complete follow-up of all patients [6] but, in practice, for outcomes other than mortality there are nearly always missing data. The CONSORT (Consolidating Standards of Reporting Trials) statemen ...
The Handbook of Clinically Tested Herbal Remedies
... imprints of The Haworth Press, Inc., 10 Alice Street, Binghamton, NY 13904-1580. © 2004 by The Haworth Press, Inc. All rights reserved. No part of this work may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, microfilm, and recording, or by an ...
... imprints of The Haworth Press, Inc., 10 Alice Street, Binghamton, NY 13904-1580. © 2004 by The Haworth Press, Inc. All rights reserved. No part of this work may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, microfilm, and recording, or by an ...
Marketed products fact sheet
... FUTURE-1 (Pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion) an open-label study, evaluated the safety and pharmacokinetics of a new dispersible tablet formulation of Tracleer. This study provided important pharmacokinetic and dosing information using the new pediatric formulation ...
... FUTURE-1 (Pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion) an open-label study, evaluated the safety and pharmacokinetics of a new dispersible tablet formulation of Tracleer. This study provided important pharmacokinetic and dosing information using the new pediatric formulation ...
Rationale, design, and organization of the
... These recommendations were primarily based on the results of 2 very small trials that claimed benefits from the use of perioperative h-blockers.11,12 These trials were limited because 1 removed events after randomization; 1 was unblinded and stopped at an interim analysis, which suggested an unexpec ...
... These recommendations were primarily based on the results of 2 very small trials that claimed benefits from the use of perioperative h-blockers.11,12 These trials were limited because 1 removed events after randomization; 1 was unblinded and stopped at an interim analysis, which suggested an unexpec ...
Monitoring of liver function tests and hepatitis in patients
... prospective study that will systematically assess changes in liver tests over time in opioid dependent patients randomized to be treated with either buprenorphine/naloxone or methadone. Results from this trial should provide more information about the effects of buprenorphine/naloxone on the liv ...
... prospective study that will systematically assess changes in liver tests over time in opioid dependent patients randomized to be treated with either buprenorphine/naloxone or methadone. Results from this trial should provide more information about the effects of buprenorphine/naloxone on the liv ...
Clinical Research Staff - Leeds Teaching Hospitals NHS Trust
... Clinical research in Leeds is increasing and in parallel the number of research staff with varying levels of experience is also growing. There are strong and established areas of research activity, some of which is world-leading, focused around our NIHR Leeds Clinical Research Facility in cancer, mu ...
... Clinical research in Leeds is increasing and in parallel the number of research staff with varying levels of experience is also growing. There are strong and established areas of research activity, some of which is world-leading, focused around our NIHR Leeds Clinical Research Facility in cancer, mu ...
STUDY REPORT
... Vasoconstriction was measured by the degree of skin blanching observed after treatment removal using a ChromaMeta (a-scale reading). Evaluations were performed at pre-dose and at 0.5, 2, 4, 6, 8, 10, 12, 20, and 24 hours after removal. Study data were collected on source documents . Completed case r ...
... Vasoconstriction was measured by the degree of skin blanching observed after treatment removal using a ChromaMeta (a-scale reading). Evaluations were performed at pre-dose and at 0.5, 2, 4, 6, 8, 10, 12, 20, and 24 hours after removal. Study data were collected on source documents . Completed case r ...
letter to CMS - Society of Nuclear Medicine
... consistent with AD. The patient was started on a cholinesterase inhibitor, advised to discontinue driving, and her daughter began overseeing her medications and finances. The results of the examination, amyloid scan, and MRI indicated that hydrocephalus was not playing a major role in her functional ...
... consistent with AD. The patient was started on a cholinesterase inhibitor, advised to discontinue driving, and her daughter began overseeing her medications and finances. The results of the examination, amyloid scan, and MRI indicated that hydrocephalus was not playing a major role in her functional ...
Off-Label / Unproven Specialty Drug Treatment
... apply. UnitedHealthcare reserves the right, in its sole discretion, to modify its Policies and Guidelines as necessary. This Drug Policy is provided for informational purposes. It does not constitute medical advice. UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Car ...
... apply. UnitedHealthcare reserves the right, in its sole discretion, to modify its Policies and Guidelines as necessary. This Drug Policy is provided for informational purposes. It does not constitute medical advice. UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Car ...
Canaccord Genuity Annual Growth Conference
... market potential of our product candidates, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly filings and annual reports. Forward-looking stat ...
... market potential of our product candidates, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly filings and annual reports. Forward-looking stat ...
developmental-behavioral pediatrics clinical privileges
... Applicant: Check off the “Requested” box for each privilege requested. Applicants have the burden of producing information deemed adequate by the Hospital for a proper evaluation of current competence, current clinical activity, and other qualifications and for resolving any doubts related to qualif ...
... Applicant: Check off the “Requested” box for each privilege requested. Applicants have the burden of producing information deemed adequate by the Hospital for a proper evaluation of current competence, current clinical activity, and other qualifications and for resolving any doubts related to qualif ...
... Criteria). Please see protocol section 8.3.1- Risks of pregabalin 2) To include a baseline platelet count so that individuals with a low blood platelet count (less than 100,000/mm3) are excluded from entry in the trial. Additionally, those individuals with a history of thrombocytopenia or a bleeding ...
(vestibular neuritis).
... electronystagmography, caloric testing and other vestibular function and balance tests), as defined by the authors. ...
... electronystagmography, caloric testing and other vestibular function and balance tests), as defined by the authors. ...
![Spiriva [product monograph]. - Boehringer Ingelheim (Canada)](http://s1.studyres.com/store/data/007836299_1-87f0be5291d15ed92ca8a70cc3c26819-300x300.png)
Spiriva [product monograph]. - Boehringer Ingelheim (Canada)
... were permitted to use all respiratory medications as prescribed by their health care providers other than inhaled anticholinergics. In total, there were 9,468 person-years of exposure to tiotropium and 8,746 person-years of exposure to placebo, which includes the 30 day follow-up period. Adverse eve ...
... were permitted to use all respiratory medications as prescribed by their health care providers other than inhaled anticholinergics. In total, there were 9,468 person-years of exposure to tiotropium and 8,746 person-years of exposure to placebo, which includes the 30 day follow-up period. Adverse eve ...